Clinical trials: Depression NOS
Hepatic Impairment
Pharmacokinetics of AGO178 in Participants With Liver Impairment
AGO178 was developed for the treatment of depression. A new formulation is being tested in the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet).
- Trial name
- NCT01531309
- Testing
- AGO178
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Buttocks Volume Loss
Clinical Study for the Evaluation of the Effectiveness of Use of a Poly-L Lactic Acid Injectable Filler for the Aesthetic Treatment of Buttocks Volume Depression
The purpose of this study is to assess the effectiveness and safety of Gana X, a Poly L-lactic acid filler for the aesthetic treatment of buttocks.
- Trial name
- PLLA (NCT05363163)
- Testing
- Gana X
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GCS Co., Ltd
Depression, Anxiety
Aiberry AI Mental Health Screening Platform
Aiberry is creating a multi-modal artificial intelligence (AI) platform that analyzes facial, audio and text features to screen for mental illness.
- Conditions
- Depression, Anxiety, Healthy
- Trial name
- NCT04994899
- Where
- 3 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Aiberry, Inc
Postpartum Depression
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
- Trial name
- NCT02285504
- Testing
- SAGE-547
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depression
Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL
The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
- Trial name
- PET (NCT00832221)
- Testing
- SEROQUEL XR (quetiapine), SEROQUEL IR (quetiapine), radioligand [11C]raclopride
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)
The study will assess safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine (AGO178) in patients with Major Depressive Disorder over a 52-week open-label phase.
- Trial name
- NCT01156415
- Testing
- AGO178
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 837 people
- Sponsor
- Novartis Pharmaceuticals
Depression
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fasting conditions.
- Trial name
- NCT00913718
- Testing
- Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Sandoz
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder (MDD), Depression in Adults
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
- Conditions
- Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
- Trial name
- EMBRACE (NCT06793397)
- Testing
- CYB003, Psychological Support
- Where
- 79 sites in United States, Australia and 6 more
- Volunteers
- 330 people
- Sponsor
- Cybin IRL Limited
Depressive Disorder, Treatment-Resistant
Epidemiology of Treatment Resistant Depression in Taiwan
The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.
- Trial name
- NCT02691520
- Volunteers
- 8,356 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression, Bipolar Disorder
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.
- Trial name
- NCT03403790
- Testing
- Quetiapine
- Where
- 47 sites in Japan
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Depression
Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients.
- Trial name
- NCT00672659
- Testing
- Citalopram + Pipamperone, Citalopram
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- PharmaNeuroBoost N.V.
Depression, Anxiety
Effects of Probiotics on Mood
Recent demonstration that probiotics administration has positive effects on depressive feelings in healthy populations suggests its possible role as an adjuvant therapy for depression in clinical populations and as a non-invasive…
- Trial name
- NCT03539263
- Testing
- Bifihappy
- Where
- Italy
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Probiotical S.p.A.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Depression, Respiratory Insufficiency
Determination of the Clinical Impact of Continuous Surveillance Monitoring (SM) and Utility of IPI.
Single site prospective observational nested study of bedside CS20p monitor on the GCF impeded into a retrospective review of the frequency of escalation of care with intermittent vitals signs compared to continuous respiratory…
- Trial name
- IPI (NCT03050983)
- Testing
- IPI
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Medtronic - MITG
Depression
Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment
This study evaluates the use of brain activity monitoring for early identification of pharmaceutical treatment efficacy and development of depression deterioration events.
- Trial name
- NCT02523105
- Testing
- EEG monitoring
- Where
- 2 sites in Israel
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brainmarc Ltd.
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, Depression
Individual Patient Esmethadone (REL-1017) Expanded Access Program
To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other…
- Trial name
- NCT06009003
- Testing
- REL-1017
- Sponsor
- Relmada Therapeutics, Inc.